Devdatt (Dev) Kurdikar is the CEO of Embecta Corp., a company focused on diabetes management solutions. Born in 1978, Dev holds an MBA from a top business school, which laid the foundation for his career in management. He became CEO...
Devdatt (Dev) Kurdikar is the CEO of Embecta Corp., a company focused on diabetes management solutions. Born in 1978, Dev holds an MBA from a top business school, which laid the foundation for his career in management. He became CEO in April 2022, shortly after Embecta's separation from BD, where he had been with the diabetes care unit. Under his leadership, the company's focus is on driving performance-based strategies that align with long-term stockholder interests. In fiscal year 2023, Dev's total compensation was approximately $1.97 million, which included a significant performance-based bonus that reflects his impact on the company’s growth. Interesting to note, he received a one-time equity grant as part of the transition to Embecta, signaling a strong commitment to the company’s future. Dev’s leadership style emphasizes transparency and alignment between executive compensation and company performance, which reflects in the company’s pay-for-performance philosophy. Outside of his role, he has a stake in the company through equity awards, which keeps him vested in Embecta’s success.